Exelixis Inc Deferred Tax Expense from Stock Options Exercised
Exelixis Inc (EXEL) reported Deferred Tax Expense from Stock Options Exercised of $57.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:DeferredTaxExpenseFromStockOptionsExercised · last filed 2017-02-27
- Exelixis Inc deferred tax expense from stock options exercised for fiscal 2016 was $57.00M, a 216.67% increase from fiscal 2015.
- Exelixis Inc deferred tax expense from stock options exercised for fiscal 2015 was $18.00M, a 12.50% increase from fiscal 2014.
- Exelixis Inc deferred tax expense from stock options exercised for fiscal 2014 was $16.00M, a 1.91% increase from fiscal 2013.
- Exelixis Inc deferred tax expense from stock options exercised for fiscal 2013 was $15.70M.
| Period end | Deferred Tax Expense from Stock Options Exercised 12 month |
|---|---|
| 2016-12-31 | $57.00M 10-K · filed 2017-02-27 |
| 2015-12-31 | $18.00M 10-K · filed 2016-02-29 |
| 2014-12-31 | $16.00M 10-K · filed 2015-03-02 |
| 2013-12-31 | $15.70M 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |